Under pressure from Public Citizen and FDA, Dermatologic and Ophthalmic Drugs Advisory Committee chair Lynn Drake withdrew her acceptance of an invitation to provide a presentation to industry on winning a favorable panel endorsement.
Two researchers say that expedited review of new drugs may have exposed some patients to safety risks that had not been well characterized.
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
What if pharmaceutical marketing could start again with a clean slate, reinvent age-old marketing instincts and put in place some things that we think would think might work a little better? What would it look like?
As healthcare marketers and their agencies develop ever more digital customer solutions like mobile medical apps, it may be time to take a fresh look at these offerings
In 2014, the "new healthcare marketing" will become more discontinuous from the old
A study says fish oil doesn't lower the risk of heart disease, and the World Health Organization greenlights Pfizer's Prevnar 13 for adults 50 and up.
It's time for a regulatory Marshall plan to help build global systems for quality and safety